Navigation Links
SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
Date:7/24/2014

Bound Brook, NJ (PRWEB) July 24, 2014

As part of the long-term strategic approach, DZS expects to manage numerous projects in the MENA region during 2014 with potential global expansion.

"We are delighted to have a preferred provider agreement with DZS to manage our clinical trials globally and in particular in the MENA region,” said Global VP of R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh Rehani. "DZS has developed excellent operational practices with a focus on utilizing eClinical software and flexible team structures that allow companies to reduce development costs yet maintain high quality services and meet timelines. This helps pharma companies to meet the many challenges of drug development."

“We are pleased to be able to partner with SBI at a strategic level. Our Sponsors are increasingly looking for innovative approaches to bring products to market effectively and efficiently,” said Greg Ambra, VP of Clinical Operations. “Our flexible project team models, collaborative approach, and proprietary eClinical Software, ClinPlus®, increases the level of collaboration and allows us to respond quickly to our Sponsor’s needs, while maintaining our focus on high quality deliverables.”

About DZS Clinical Services:
DZS Clinical Services is a full-service Contract Research Organization providing clinical trial services and eClinical software for the biotech and pharmaceutical industry. DZS Clinical Services is a division of DZS Software Solutions, Inc., a privately held company founded in 1984. Over 60 clients globally use DZS services and software for trial monitoring and management, data capture, data cleaning, analysis, and reporting. When ClinPlus® software is coupled with DZS services and training, clients have dramatically improved productivity and maximized the value of R&D investments by obtaining fast, high-quality results leading to better
'/>"/>

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
2. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
3. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
4. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
5. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
6. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
7. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
8. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
9. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
10. Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin
11. Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... 2015 , ... R-Biopharm is proud to announce the RIDASCREEN® ... foods, has been accepted by AOAC International as Official First Action method. The ... Products by R5 Competitive ELISA,” based on a specific monoclonal antibody to potentially ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... 2015 According to a new ... Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract ... Trial), by End Users - Global Forecast to 2020", ... reach USD 2,107.99 million by 2020 from USD 1,034.93 ... Browse more than 75 ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... Nov. 21, 2011 Double Eagle Holdings, Ltd. (OTCQB: DROP), ... announced last week a partnership with golf superstar Tiger Woods ... his bag. Woods and CEO of FUSE Science Adam Adler ... partnership on CNBC today Monday, November 21, at 12:30 p.m. ...
... The report " Leukemia Therapeutics Market (Acute/Chronic ... Global Market Forecast (2010 - 2020) " ... opportunities in North America, & Europe. ... Leukemia Therapeutics Market (Acute/Chronic Lymphocytic Leukemia & Acute/Chronic Myeloid ...
... 2011 - A research group from RIKEN, the University ... today announced that research results obtained using the "K ... at SC11, the International Conference for High Performance Computing, ... November 17 (US Pacific Standard Time). The award-winning ...
Cached Biology Technology:Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement! 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3'K computer' research results awarded ACM Gordon Bell Prize 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... Studies show 97 percent of American adults get less ... the minimum recommended amount based on federal guidelines. New ... traits may predispose people to being more or less ... professor in the MU College of Veterinary Medicine, along ...
... Barcelona have discovered new clues about past rapid climate ... journal Nature Geoscience , concludes that oceanographic reorganisations ... airborne dust in the Southern Ocean and this connection ... atmospheric carbon dioxide levels, an important component in the ...
... A team of researchers, led by Marc Freeman, PhD, an ... associate professor of neurobiology at the University of Massachusetts Medical ... Drosophila melanogaster that, when mutant, blocks the self-destruction of ... diseases, such as amyotrophic lateral sclerosis (ALS). A ...
Cached Biology News:Couch potatoes may be genetically predisposed to being lazy, MU study finds 2Rapid climate change and the role of the Southern Ocean 2A fly mutation suggests a new route for tackling ALS 2A fly mutation suggests a new route for tackling ALS 3
PKC (pSer345), phospho-specific...
MAB3246 recognizes the neuro-endocrine specific protein (NSP) C....
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Biology Products: